Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

7.4%

2 terminated out of 27 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed with results

Key Signals

3 with results67% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (1)
P 1 (15)
P 2 (9)

Trial Status

Recruiting11
Active Not Recruiting4
Completed4
Unknown4
Terminated2
Withdrawn1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT04616560Phase 1RecruitingPrimary

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

NCT04145349Phase 1CompletedPrimary

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

NCT04022213Phase 2Active Not RecruitingPrimary

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

NCT07695311Phase 1Not Yet Recruiting

EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT

NCT06625190Phase 1Recruiting

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT07328425Phase 2RecruitingPrimary

Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS

NCT04897321Phase 1Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT04483778Phase 1Active Not Recruiting

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT05918640Phase 1Recruiting

Lurbinectedin in FET-Fused Tumors

NCT01946529Phase 2Active Not RecruitingPrimary

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

NCT06709495Phase 1Recruiting

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

NCT03967834Not ApplicableRecruiting

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

NCT04690374RecruitingPrimary

Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor

NCT06849986Phase 2Recruiting

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

NCT03618381Phase 1Active Not Recruiting

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT06277154Phase 2Recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

NCT04530487Phase 2TerminatedPrimary

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

NCT01125449Phase 2Withdrawn

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

NCT04095221Phase 1CompletedPrimary

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

NCT06456359Phase 2RecruitingPrimary

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Scroll to load more

Research Network

Activity Timeline